{"version ": "BioASQ6b", "data": [{"title": "BioASQ6b", "paragraphs": [{"qas": [{"id": "54e25eaaae9738404b000017_001", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin. "}, {"qas": [{"id": "54e25eaaae9738404b000017_002", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration. Both MIG-6 isoforms have a predicted N-terminal papilin cassette"}, {"qas": [{"id": "54e25eaaae9738404b000017_003", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains. "}, {"qas": [{"id": "54e25eaaae9738404b000017_004", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance. This review samples some of the contemporary literature regarding TSR superfamily members (e.g. F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains."}, {"qas": [{"id": "54e25eaaae9738404b000017_005", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Papilins are extracellular matrix proteins "}, {"qas": [{"id": "54e25eaaae9738404b000017_006", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Papilin is an extracellular matrix glycoprotein "}, {"qas": [{"id": "54e25eaaae9738404b000017_007", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium. "}, {"qas": [{"id": "54e25eaaae9738404b000017_008", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin."}, {"qas": [{"id": "535d292a9a4572de6f000003_001", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."}, {"qas": [{"id": "535d292a9a4572de6f000003_002", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases."}, {"qas": [{"id": "535d292a9a4572de6f000003_003", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans. We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts"}, {"qas": [{"id": "535d292a9a4572de6f000003_004", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning."}, {"qas": [{"id": "535d292a9a4572de6f000003_005", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs. "}, {"qas": [{"id": "535d292a9a4572de6f000003_006", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function."}, {"qas": [{"id": "55262a9787ecba3764000009_001", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-\u03baB ligand (RANKL) "}, {"qas": [{"id": "55262a9787ecba3764000009_002", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily. It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL)."}, {"qas": [{"id": "55262a9787ecba3764000009_003", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis"}, {"qas": [{"id": "55262a9787ecba3764000009_004", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation"}, {"qas": [{"id": "55262a9787ecba3764000009_005", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL."}, {"qas": [{"id": "55262a9787ecba3764000009_006", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL."}, {"qas": [{"id": "55262a9787ecba3764000009_007", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption"}, {"qas": [{"id": "55262a9787ecba3764000009_008", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts"}, {"qas": [{"id": "55262a9787ecba3764000009_009", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice. "}, {"qas": [{"id": "55262a9787ecba3764000009_010", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": " osteoclastogenesis and bone destruction in autoimmune arthritis. We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis."}, {"qas": [{"id": "55262a9787ecba3764000009_011", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor \u03baB ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts. "}, {"qas": [{"id": "52bf1db603868f1b06000011_001", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors."}, {"qas": [{"id": "52bf1db603868f1b06000011_002", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " The authors present the imaging findings and technical report of an attempted percutaneous vertebroplasty in the only patient found to be actively under treatment with denosumab after a retrospective review of the databank of patients with pathological fractures referred to the Department Radiology of the Ohio State University for percutaneous vertebroplasty (a total sample of 20 patients) since the FDA approval of denosumab (November 2010) until June of 2013 (a 30-month period)."}, {"qas": [{"id": "52bf1db603868f1b06000011_003", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "On the basis of this data, the FDA approved denosumab for the treatment of patients whose GCTB is unresectable, or when surgery is likely to result in severe morbidity."}, {"qas": [{"id": "52bf1db603868f1b06000011_004", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010."}, {"qas": [{"id": "52bf1db603868f1b06000011_005", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recent phase II clinical trials with denosumab in skeletally mature adolescents over age 12 years and adults with GCTB, have shown both safety and efficacy, leading to its accelerated US FDA approval on 13 June 2013. "}, {"qas": [{"id": "52bf1db603868f1b06000011_006", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Zoledronic acid (ZA), an intravenously administered bisphosphonate, and Denosumab, a subcutaneously administered inhibitor of nuclear factor B ligand (RANKL), have already been approved by Food and Drug Administration (FDA) for their use in treatment of bone metastases."}, {"qas": [{"id": "52bf1db603868f1b06000011_007", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "These results led to the approval of denosumab by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), for the prevention of SREs in adults with bone metastases from solid tumors, including breast cancer."}, {"qas": [{"id": "52bf1db603868f1b06000011_008", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options. "}, {"qas": [{"id": "52bf1db603868f1b06000011_009", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Several of these therapies have recently been approved by the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human clinical trials (tanezumab)."}, {"qas": [{"id": "52bf1db603868f1b06000011_010", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "A fourth agent, denosumab (bone targeted therapy) was also recently approved by the FDA for patients with bone metastasis after showing a reduction in the occurrence of skeletal-related events. "}, {"qas": [{"id": "52bf1db603868f1b06000011_011", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010). "}, {"qas": [{"id": "52bf1db603868f1b06000011_012", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel-T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. "}, {"qas": [{"id": "52bf1db603868f1b06000011_013", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer."}, {"qas": [{"id": "52bf1db603868f1b06000011_014", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "In addition to these new and emerging therapeutic agents, denosumab was approved for the prevention of skeletal complications in patients with bone metastases due to solid tumor malignancies, providing an alternative to zoledronic acid. "}, {"qas": [{"id": "52bf1db603868f1b06000011_015", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recently, denosumab was FDA-approved for prevention of SREs in patients with bone metastases from solid tumors. "}, {"qas": [{"id": "52bf1db603868f1b06000011_016", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011."}, {"qas": [{"id": "52bf1db603868f1b06000011_017", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases. "}, {"qas": [{"id": "52bf1db603868f1b06000011_018", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA). "}, {"qas": [{"id": "52bf1db603868f1b06000011_019", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. "}, {"qas": [{"id": "52bf1db603868f1b06000011_020", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis."}, {"qas": [{"id": "52bf1db603868f1b06000011_021", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray. "}, {"qas": [{"id": "52bf1db603868f1b06000011_022", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab. "}, {"qas": [{"id": "5313b049e3eabad021000013_001", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Herceptin is widely used in treating Her2-overexpressing breast cancer. However, the application of Herceptin in prostate cancer is still controversial."}, {"qas": [{"id": "5313b049e3eabad021000013_002", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Our data demonstrate that Re-188-labeled Herceptin effectively inhibited the growth of DU145 cells compared to the Herceptin- and Re-188-treated cohorts. This implies that targeting Her2 by both radio- and immuno- therapy might be a potential strategy for treating patients with androgen-independent prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_003", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "epidermal growth factor receptor (EGFR) family members are potential targets for therapy using extra-cellular domain receptor binding agents, such as the antibodies trastuzumab and cetuximab"}, {"qas": [{"id": "5313b049e3eabad021000013_004", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": " there were tendencies for upregulation of HER2, increased co-expression of EGFR and HER2 and downregulation of HER3 in the prostate cancer lymph node metastases in comparison to the primary tumors. "}, {"qas": [{"id": "5313b049e3eabad021000013_005", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "We performed a comparative analysis in vitro and in vivo of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (trastuzumab), 2C4 (pertuzumab) and Erb-hcAb (human anti-ErbB2-compact antibody), a novel fully human compact antibody produced in our laboratory. Herein, we demonstrate that the growth of both androgen-dependent and independent prostate cancer cells was efficiently inhibited by Erb-hcAb. The antitumor effects induced by Erb-hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4."}, {"qas": [{"id": "5313b049e3eabad021000013_006", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "These findings suggest that a systemic delivery of 212Pb-trastuzumab could             be an effective modality for management of advanced human prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_007", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Human epidermal growth factor receptor type 2 (HER2) overexpression supports proliferation of androgen-independent prostate cancer (PC)"}, {"qas": [{"id": "5313b049e3eabad021000013_008", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Radiolabeled ABY-025 Affibody molecule provides higher contrast in imaging of HER2-expressing PC xenografts than radiolabeled trastuzumab. "}, {"qas": [{"id": "5313b049e3eabad021000013_009", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "These studies indicate that dual EGFR/HER2 inhibition, administered together with AWT, sensitize prostate cancer cells to apoptosis during AWT"}, {"qas": [{"id": "5313b049e3eabad021000013_010", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "The overall goal of these studies is to determine whether dual inhibition of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and HER2 would prolong the effectiveness of this treatment in prostate cancer. "}, {"qas": [{"id": "5313b049e3eabad021000013_011", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "The expression of HER2 was demonstrated and quantified in all three tested prostate cancer cell-lines."}, {"qas": [{"id": "5313b049e3eabad021000013_012", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Such features would definitely favor the use of radiometal labels for trastuzumab and, most likely, for affibody molecules"}, {"qas": [{"id": "5313b049e3eabad021000013_013", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "our data demonstrate that Her2 plays an important role in the support of AR protein stability in the transition of androgen requirement in prostate cancer cells. We hope these findings will provide novel insight into the treatment of hormone-refractory prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_014", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "These two cell lines exhibited distinct responses to Her2 activation (by heregulin treatment) on Her2 phosphorylation and Her2 inhibition (by AG825 or Herceptin treatments) on proliferation"}, {"qas": [{"id": "5313b049e3eabad021000013_015", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": " While prostate cancers that express high levels of HER-2 are resistant to the killing effects of trastuzumab, they can be targeted for selective gene expression and destruction by lentiviruses with envelope proteins engineered to bind to this therapeutic antibody"}, {"qas": [{"id": "5313b049e3eabad021000013_016", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Overexpression of ErbB-2 and EGFR has been associated with aggressive disease and poor patient prognosis in a range of human tumour types (e.g. breast, lung, ovarian, prostate"}, {"qas": [{"id": "5313b049e3eabad021000013_017", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Various approaches have been developed to target the ErbB signalling pathways including monoclonal antibodies (trastuzumab/Herceptin"}, {"qas": [{"id": "5313b049e3eabad021000013_018", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "The data from these in vitro and in vivo studies supported advancement of radiolabeled trastuzumab into two clinical studies"}, {"qas": [{"id": "5313b049e3eabad021000013_019", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Tumor targeting was evaluated in mice bearing subcutaneous (s.c.) xenografts of colorectal, pancreatic, ovarian, and prostate carcinomas."}, {"qas": [{"id": "5313b049e3eabad021000013_020", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "we found that although prostate cancers that express high levels of HER-2 are resistant to the killing effects of trastuzumab, they can be targeted for selective gene expression and destruction by viruses with envelope proteins engineered to bind this antibody"}, {"qas": [{"id": "5313b049e3eabad021000013_021", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "detection of prostate cancer (PCa) and advances in hormonal and chemotherapy treatments have provided great clinical benefits to patients with early stages of the disease."}, {"qas": [{"id": "5313b049e3eabad021000013_022", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "MAbs directed to established targets include those approved for other solid tumors, including anti-human epidermal growth factor receptor-2 (HER2) MAb trastuzumab"}, {"qas": [{"id": "5313b049e3eabad021000013_023", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "We conclude that Her2/neu expression in the peripheral blood mononuclear cell fraction of prostate cancer patients is frequent and therefore this assay may potentially be useful to detect the presence of micrometastatic disease in men with prostate cancer and for monitoring patients enrolled in trastuzumab-based therapeutic protocols."}, {"qas": [{"id": "5313b049e3eabad021000013_024", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "This study suggests that the docetaxel/trastuzumab combination may prove an effective therapeutic approach for HER2-expressing hormone-refractory prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_025", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "there was no significant difference in antimetastatic activity between the emulsion and the immunoemulsion despite the affinity of the immunoemulsion towards the HER2 receptor. "}, {"qas": [{"id": "5313b049e3eabad021000013_026", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "a targeted drug delivery system based on cationic emulsion covalently linked to anti-HER2 monoclonal antibody (Herceptin), in a well-established in vivo pharmacologic model of metastatic prostate cancer that overexpresses the HER2 receptor"}, {"qas": [{"id": "5313b049e3eabad021000013_027", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour."}, {"qas": [{"id": "5313b049e3eabad021000013_028", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Although HER2 can be over-expressed in prostate cancer, there is no clinical data to support the use of trastuzumab for prostate cancer patients."}, {"qas": [{"id": "5313b049e3eabad021000013_029", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "whereas the effect of the trastuzumab-RT combination was inferior to that predicted by the individual effects."}, {"qas": [{"id": "5313b049e3eabad021000013_030", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab"}, {"qas": [{"id": "5313b049e3eabad021000013_031", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Trastuzumab (Herceptin) as a single agent demonstrated poor efficacy in treating HRPC."}, {"qas": [{"id": "5313b049e3eabad021000013_032", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)"}, {"qas": [{"id": "5313b049e3eabad021000013_033", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Conclusions regarding the predictive value of HER-2 status on outcome after trastuzumab-based therapy were not reached and were only drawn after larger-scale screening efforts. "}, {"qas": [{"id": "5313b049e3eabad021000013_034", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "rastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma"}, {"qas": [{"id": "5313b049e3eabad021000013_035", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "clinical trials are currently in progress in patients with prostate cancer testing novel agents that selectively interfere with these receptors, such as trastuzumab,"}, {"qas": [{"id": "5313b049e3eabad021000013_036", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "ytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate"}, {"qas": [{"id": "5313b049e3eabad021000013_037", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "The clinical interpretation of c-erbB-2 abnormalities should reflect the complexity of c-erbB-2 mediated regulatory pathway and explain why tumours with overexpression/amplification of c-erbB-2 very often do not respond to therapy using Herceptin"}, {"qas": [{"id": "5313b049e3eabad021000013_038", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "HER-2 overexpression also has been reported in up to 60% of patients with hormone-refractory prostate carcinoma (HRPC) and was correlated with shortened survival"}, {"qas": [{"id": "5313b049e3eabad021000013_039", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Unlike breast carcinoma and contrary to prior reports, HER-2 overexpression by IHC in archival prostate tissue from patients who eventually developed hormone-refractory disease was infrequent. There did not appear to be any correlation between HER-2 overexpression by IHC and shed HER-2 antigen levels in serum by ELISA in this tumor type."}, {"qas": [{"id": "5313b049e3eabad021000013_040", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Further development of trastuzumab for the treatment of patients with metastatic prostate carcinoma is not feasible until more reliable and practical methods of sampling metastatic disease are developed to identify patients with HER-2 positive tumors."}, {"qas": [{"id": "5313b049e3eabad021000013_041", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "the expression of ERBB2 in prostate cancer is relatively low, and is not altered during disease progression. Thus, it is unlikely that treatment modalities relying on the overexpression of ERBB2 gene will be useful in treating prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_042", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "A phase I study was designed to evaluate docetaxel/estramustine plus trastuzumab, a humanized monoclonal antibody that binds to the HER2 receptor, in patients with metastatic androgen-independent prostate cancer (AIPC)"}, {"qas": [{"id": "5313b049e3eabad021000013_043", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Laboratory evidence also supports the clinical evaluation of docetaxel-based combinations that include agents such as trastuzumab and/or estramustine"}, {"qas": [{"id": "5313b049e3eabad021000013_044", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "trastuzumab, a monoclonal antibody binding to the HER2 receptor; immunotoxin conjugates use an antibody directed against EGFR joined to a cell toxin. All are in clinical trials for a number of cancers, including prostate cancer"}, {"qas": [{"id": "5313b049e3eabad021000013_045", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "we investigated the antitumor efficacy of Herceptin, a new recombinant humanized anti-HER2/neu antibody, which exhibits cytostatic activity on breast and prostate cancer cells that overexpress the HER2 oncogene."}, {"qas": [{"id": "5313b049e3eabad021000013_046", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "trastuzumab was found to have additive and synergistic effects with some chemotherapeutic agents"}, {"qas": [{"id": "5313b049e3eabad021000013_047", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "ER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer"}, {"qas": [{"id": "5313b049e3eabad021000013_048", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "in these prostate cancer model systems, Herceptin alone has clinical activity only in the androgen-dependent tumor and has at least an additive effect on growth,"}, {"qas": [{"id": "5313b049e3eabad021000013_049", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "anti-HER2 receptor monoclonal antibody Herceptin significantly enhanced growth inhibition of the MDA PCa 2a cells."}, {"qas": [{"id": "517395b98ed59a060a00001a_001", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": ", as splicing is often cotranscriptional, a complex picture emerges in which splicing regulation not only depends on the balance of splicing factor binding to their pre-mRNA target sites but also on transcription-associated features such as protein recruitment to the transcribing machinery and elongation kinetics."}, {"qas": [{"id": "517395b98ed59a060a00001a_002", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "recent evidence shows that chromatin structure is another layer of regulation that may act through various mechanisms"}, {"qas": [{"id": "517395b98ed59a060a00001a_003", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "hese span from regulation of RNA polymerase II elongation, which ultimately determines splicing decisions, to splicing factor recruitment by specific histone marks."}, {"qas": [{"id": "517395b98ed59a060a00001a_004", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Chromatin may not only be involved in alternative splicing regulation but in constitutive exon recognition as well"}, {"qas": [{"id": "517395b98ed59a060a00001a_005", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure."}, {"qas": [{"id": "517395b98ed59a060a00001a_006", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "These links between chromatin configuration and splicing raise the intriguing possibility of the existence of a memory for splicing patterns to be inherited through epigenetic modifications."}, {"qas": [{"id": "517395b98ed59a060a00001a_007", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Spliceosome assembly occurs co-transcriptionally, raising the possibility that DNA structure may directly influence alternative splicing."}, {"qas": [{"id": "517395b98ed59a060a00001a_008", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "upporting such an association, recent reports have identified distinct histone methylation patterns, elevated nucleosome occupancy and enriched DNA methylation at exons relative to introns"}, {"qas": [{"id": "517395b98ed59a060a00001a_009", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Moreover, the rate of transcription elongation has been linked to alternative splicing."}, {"qas": [{"id": "517395b98ed59a060a00001a_010", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "ere we provide the first evidence that a DNA-binding protein, CCCTC-binding factor (CTCF), can promote inclusion of weak upstream exons by mediating local RNA polymerase II pausing both in a mammalian model system for alternative splicing, CD45, and genome-wide"}, {"qas": [{"id": "517395b98ed59a060a00001a_011", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "We recently showed that cotranscriptional splicing occurs efficiently in Drosophila,"}, {"qas": [{"id": "517395b98ed59a060a00001a_012", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "In recent years it became apparent that splicing is predominantly cotranscriptional"}, {"qas": [{"id": "517395b98ed59a060a00001a_013", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "To determine the prevalence of cotranscriptional splicing in Drosophila, we sequenced nascent RNA transcripts from Drosophila S2 cells as well as from Drosophila heads. Eighty-seven percent of the introns assayed manifest >50% cotranscriptional splicing. The remaining 13% are cotranscriptionally spliced poorly or slowly, with \u223c3% being almost completely retained in nascent pre-mRNA."}, {"qas": [{"id": "517395b98ed59a060a00001a_014", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "We estimate that > or =90% of endogenous yeast splicing is posttranscriptional, consistent with an analysis of posttranscriptional snRNP-associated pre-mRNA."}, {"qas": [{"id": "517395b98ed59a060a00001a_015", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Notably, the topoisomerase I inhibitor camptothecin, which stalls elongating Pol II, increased cotranscriptional splicing factor accumulation and splicing in parallel. This provides direct evidence for a kinetic link between transcription, splicing factor recruitment and splicing catalysis."}, {"qas": [{"id": "517395b98ed59a060a00001a_016", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "Recent evidence indicates that transcriptional elongation and splicing can be influenced reciprocally: Elongation rates control alternative splicing and splicing factors can, in turn, modulate pol II elongation."}, {"qas": [{"id": "517395b98ed59a060a00001a_017", "question": "Are transcription and splicing connected?", "is_impossible": false, "answers": "yes"}], "context": "The presence of transcription factors in the spliceosome and the existence of proteins, such as the coactivator PGC-1, with dual activities in splicing and transcription can explain the links between both processes and add a new level of complexity to the regulation of gene expression in eukaryotes."}, {"qas": [{"id": "54db1d580f63c58e6e000005_001", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer"}, {"qas": [{"id": "54db1d580f63c58e6e000005_002", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "In IBC, Alu hypomethylation correlated with negative estrogen receptor (ER) status"}, {"qas": [{"id": "54db1d580f63c58e6e000005_003", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "In survival analyses, low Alu methylation status tended to be associated with poor disease-free survival of the patients."}, {"qas": [{"id": "54db1d580f63c58e6e000005_004", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "Alu hypomethylation is probably a late event during breast cancer progression"}, {"qas": [{"id": "54db1d580f63c58e6e000005_005", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "prominent hypomethylation of Alu and LINE-1 in HER2 enriched subtype may be related to chromosomal instability of this specific subtype."}, {"qas": [{"id": "54db1d580f63c58e6e000005_006", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "DNA methylation for three repetitive elements (LINE1, Sat2 and Alu) were analyzed in invasive ductal carcinoma of the breast, paired adjacent normal tissue and WBC from 40 breast cancer patients"}, {"qas": [{"id": "54db1d580f63c58e6e000005_007", "question": "Is Alu hypomethylation associated with breast cancer?", "is_impossible": false, "answers": "yes"}], "context": "DNA methylation for the three repetitive elements was lower in tumor compared to adjacent tissue and WBC DNA."}, {"qas": [{"id": "56bf365eef6e39474100000e_001", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "The recent identification of somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas."}, {"qas": [{"id": "56bf365eef6e39474100000e_002", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "A mutation in PIK3CA or AKT1 was found in around 9 % of the cases."}, {"qas": [{"id": "56bf365eef6e39474100000e_003", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry."}, {"qas": [{"id": "56bf365eef6e39474100000e_004", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas. "}, {"qas": [{"id": "56bf365eef6e39474100000e_005", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "We observed strong up-regulation of SFRP1 expression in all meningiomas with AKT1E17K mutation and in HEK293 cells after transfection with mutant AKT1E17K, but not in meningiomas and HEK293 cells lacking this mutation."}, {"qas": [{"id": "56bf365eef6e39474100000e_006", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "SMO and AKT1 mutations occur in non-NF2 meningiomas."}, {"qas": [{"id": "56bf365eef6e39474100000e_007", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Recurrent mutations in SMO and AKT1 are mutually exclusive with NF2 loss in meningioma."}, {"qas": [{"id": "56bf365eef6e39474100000e_008", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations."}, {"qas": [{"id": "56bf365eef6e39474100000e_009", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": " A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways."}, {"qas": [{"id": "56bf365eef6e39474100000e_010", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO."}, {"qas": [{"id": "56bf365eef6e39474100000e_011", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways."}, {"qas": [{"id": "56bf365eef6e39474100000e_012", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "SMO and AKT1 mutations occur in non-NF2 meningiomas"}, {"qas": [{"id": "56bf365eef6e39474100000e_013", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "The recent identification of somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas"}, {"qas": [{"id": "56bf365eef6e39474100000e_014", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways"}, {"qas": [{"id": "56bf365eef6e39474100000e_015", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO"}, {"qas": [{"id": "56bf365eef6e39474100000e_016", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations"}, {"qas": [{"id": "56bf365eef6e39474100000e_017", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "Recurrent mutations in SMO and AKT1 are mutually exclusive with NF2 loss in meningioma"}, {"qas": [{"id": "56bf365eef6e39474100000e_018", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. These mutations were present in therapeutically challenging tumors of the skull base and higher grade. "}, {"qas": [{"id": "56bf365eef6e39474100000e_019", "question": "Do mutations of AKT1 occur in meningiomas?", "is_impossible": false, "answers": "yes"}], "context": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. "}, {"qas": [{"id": "5158644cd24251bc0500008e_001", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Increases in blood PYY(3-36) levels were dependent on the exercise intensity (effect of session: P<0.001 by two-way ANOVA), whereas those in GLP-1 levels were similar between two different exercise sessions."}, {"qas": [{"id": "5158644cd24251bc0500008e_002", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "A decrease in serum leptin levels (-48.4%, p < 0.001) was observed after intervention without changes in total peptide YY and insulin levels."}, {"qas": [{"id": "5158644cd24251bc0500008e_003", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation"}, {"qas": [{"id": "5158644cd24251bc0500008e_004", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Hunger and gut hormones remained unchanged during the bed rest."}, {"qas": [{"id": "5158644cd24251bc0500008e_005", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "weight-bearing exercise has a greater exercise-induced appetite suppressive effect compared with non-weight-bearing exercise, and both forms of exercise lowered acylated ghrelin and increased total PYY, but the changes did not differ significantly between exercise modes."}, {"qas": [{"id": "5158644cd24251bc0500008e_006", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Appetite (P\u00a0<\u00a00.0005) and acylated ghrelin (P\u00a0<\u00a00.002) were suppressed during exercise but more so during SIE. Peptide YY increased during exercise but most consistently during END (P\u00a0<\u00a00.05). Acylated ghrelin was lowest in the afternoon of SIE (P\u00a0=\u00a00.018) despite elevated appetite"}, {"qas": [{"id": "5158644cd24251bc0500008e_007", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Following the pre-exercise meal, ghrelin was suppressed ~17% and insulin and PYY were elevated ~157 and ~40%, respectively, relative to fasting (day 7). Following exercise, PYY, ghrelin, and GH were significantly (p < 0.0001) increased by ~11, ~16 and ~813%, respectively. The noted disruption in the typical inverse relationship between ghrelin and PYY following exercise suggests that interaction of these peptides may be at least partially responsible for post-exercise appetite suppression"}, {"qas": [{"id": "5158644cd24251bc0500008e_008", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Plasma levels of PYY and GLP-1 were increased by exercise, whereas plasma ghrelin levels were unaffected by exercise"}, {"qas": [{"id": "5158644cd24251bc0500008e_009", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "These findings suggest ghrelin and PYY may regulate appetite during and after exercise,"}, {"qas": [{"id": "5158644cd24251bc0500008e_010", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "significant (P < 0.05) interaction effects for hunger, acylated ghrelin, and PYY, indicating suppressed hunger and acylated ghrelin during aerobic and resistance exercise and increased PYY during aerobic exercise"}, {"qas": [{"id": "5158644cd24251bc0500008e_011", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "'exercise-induced anorexia' may potentially be linked to increased PYY, GLP-1 and PP levels."}, {"qas": [{"id": "5158644cd24251bc0500008e_012", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Hunger scores and PYY, GLP-1 and PP levels showed an inverse temporal pattern during the 1-h exercise/control intervention"}, {"qas": [{"id": "5158644cd24251bc0500008e_013", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Exercise significantly increased mean PYY, GLP-1 and PP levels, and this effect was maintained during the post-exercise period for GLP-1 and PP. No significant effect of exercise was observed on postprandial levels of ghrelin"}, {"qas": [{"id": "5158644cd24251bc0500008e_014", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "following blood donation the strenuous exercise resulted in a marked reduction in the plasma leptin"}, {"qas": [{"id": "5158644cd24251bc0500008e_015", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation"}, {"qas": [{"id": "5158644cd24251bc0500008e_016", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "the unrestricted exercise group has a significantly elevated SRIF-LI concentration"}, {"qas": [{"id": "5158644cd24251bc0500008e_017", "question": "Does physical activity influence gut hormones?", "is_impossible": false, "answers": "yes"}], "context": "Exercise has recently been reported to influence ghrelin and PYY concentrations."}, {"qas": [{"id": "54f08d4a94afd61504000016_001", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "CONCLUSIONS: Comorbid pain syndromes, mood conditions and asthma are common in adolescents and young women with endometriosis."}, {"qas": [{"id": "54f08d4a94afd61504000016_002", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "There are many etiologies of pelvic pain that present with symptoms resembling those of endometriosis-associated pelvic pain that are not diagnosable with laparoscopy, such as interstitial cystitis and irritable bowel syndrome."}, {"qas": [{"id": "54f08d4a94afd61504000016_003", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Often, such patients are labelled with irritable bowel syndrome. "}, {"qas": [{"id": "54f08d4a94afd61504000016_004", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Irritable bowel syndrome (IBS) is also common in this setting, and it was speculated that the visceral hypersensitivity associated with this condition might be amplifying the symptoms of endometriosis. "}, {"qas": [{"id": "54f08d4a94afd61504000016_005", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "RESULTS: Compared with controls, patients with minimal to mild and moderate to severe endometriosis had a higher prevalence of symptoms consistent with IBS (0% vs 65% and 50%, respectively, p<0.001) with significantly lower mean pain thresholds (39.5 mm\u2002Hg (95% CI 36.0 to 43.0) vs 28.1 mm\u2002Hg (95% CI 24.5 to 31.6), p=0.001 and 28.8 mm\u2002Hg (95% CI 24.9 to 32.6), p=0.002) not explained by differences in rectal compliance. "}, {"qas": [{"id": "54f08d4a94afd61504000016_006", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.9, 95% CI (1.03-3.87)]."}, {"qas": [{"id": "54f08d4a94afd61504000016_007", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "A weak association between reported family history of endometriosis and history of irritable bowel syndrome and the development of endometriosis was also observed. "}, {"qas": [{"id": "54f08d4a94afd61504000016_008", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Irritable bowel syndrome and chronic constipation in patients with endometriosis."}, {"qas": [{"id": "54f08d4a94afd61504000016_009", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Fifteen per cent of the patients with endometriosis also had IBS and 14% of the patients with endometriosis had functional constipation without IBS."}, {"qas": [{"id": "54f08d4a94afd61504000016_010", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "CONCLUSION: In patients with endometriosis, 29% also had IBS or constipation. "}, {"qas": [{"id": "54f08d4a94afd61504000016_011", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed."}, {"qas": [{"id": "54f08d4a94afd61504000016_012", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Compared with controls, women with endometriosis had increased risks of abdominopelvic pain (OR 5.2 [95% CI: 4.7-5.7]), dysmenorrhoea (OR 8.1 [95% CI: 7.2-9.3]), menorrhagia (OR 4.0 [95% CI: 3.5-4.5]), subfertility (OR 8.2 [95% CI: 6.9-9.9]), dyspareunia and/or postcoital bleeding (OR 6.8 [95% CI: 5.7-8.2]), and ovarian cysts (OR 7.3 [95% CI: 5.7-9.4]), and of being diagnosed with irritable bowel syndrome (IBS) (OR 1.6 [95% CI: 1.3-1.8]) or pelvic inflammatory disease (OR 3.0 [95% CI: 2.5-3.6])."}, {"qas": [{"id": "54f08d4a94afd61504000016_013", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Endometriosis may coexist with or be misdiagnosed as pelvic inflammatory disease or IBS."}, {"qas": [{"id": "54f08d4a94afd61504000016_014", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "RESULTS: Compared with the controls, women with endometriosis were 3.5 times more likely to have received a diagnosis of IBS (OR 3.5 [95% CI: 3.1-3.9]). Even after women had been diagnosed with endometriosis, they were still two and a half times more likely to receive a new diagnosis of IBS when compared with the controls (OR 2.5 [95% CI: 2.2-2.8])."}, {"qas": [{"id": "54f08d4a94afd61504000016_015", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "CONCLUSIONS: Women with endometriosis are more likely to be diagnosed with IBS and PID than controls, even after a definitive diagnosis of endometriosis has been reached."}, {"qas": [{"id": "54f08d4a94afd61504000016_016", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "In women, clinical studies suggest that functional pain syndromes such as irritable bowel syndrome, interstitial cystitis, and fibromyalgia, are co-morbid with endometriosis, chronic pelvic pain, and others diseases."}, {"qas": [{"id": "54f08d4a94afd61504000016_017", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "In women, clinical studies suggest that pain syndromes such as irritable bowel syndrome and interstitial cystitis, which are associated with visceral hyperalgesia, are often comorbid with endometriosis and chronic pelvic pain. "}, {"qas": [{"id": "54f08d4a94afd61504000016_018", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Depression, anxiety, IBS, FM, CFS, and IC were more common in migraine with EM group than in controls."}, {"qas": [{"id": "54f08d4a94afd61504000016_019", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Intestinal endometriosis can mimic many gastrointestinal diseases, such as irritable bowel syndrome, inflammatory bowel disease, infections and neoplasms."}, {"qas": [{"id": "54f08d4a94afd61504000016_020", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Endometriosis is often associated with other painful conditions such as irritable bowel syndrome, interstitial cystitis and fibromyalgia. "}, {"qas": [{"id": "54f08d4a94afd61504000016_021", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "CONCLUSIONS: Diagnosis of endometriosis should be considered in women with recurrent monthly abdominal pain and bowel symptoms, especially if accompanied by gynaecologic complaints, even because the significant symptoms overlap with the irritable bowel syndrome (IBS) and makes the differentiation extremely difficult."}, {"qas": [{"id": "54f08d4a94afd61504000016_022", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Intestinal endometriosis is typically asymptomatic; however, when symptoms occur, they can mimic those of irritable bowel syndrome."}, {"qas": [{"id": "54f08d4a94afd61504000016_023", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": " Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1."}, {"qas": [{"id": "54f08d4a94afd61504000016_024", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Irritable bowel syndrome (IBS) is also common in this setting, and it was speculated that the visceral hypersensitivity associated with this condition might be amplifying the symptoms of endometriosis."}, {"qas": [{"id": "54f08d4a94afd61504000016_025", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "is_impossible": false, "answers": "yes"}], "context": "Irritable bowel syndrome (IBS) is also common in this setting, and it was speculated that the visceral hypersensitivity associated with this condition might be amplifying the symptoms of endometriosis."}, {"qas": [{"id": "531d2aa5267d7dd053000003_001", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "NT-pro-BNP was significantly elevated postexercise in both adults and adolescents and remained above baseline at 24 h in both groups."}, {"qas": [{"id": "531d2aa5267d7dd053000003_002", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "NT-pro-BNP concentrations increased significantly (28 +/- 17.1 vs 795 +/- 823 ng x L, P < 0.05), whereas postrace cTnT were elevated in just five athletes (20%)."}, {"qas": [{"id": "531d2aa5267d7dd053000003_003", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "[NT-pro-BNP] was observed immediately after the marathon (median [NT-pro-BNP] before: 39.6 pg ml(-1), after: 138.6 pg ml(-1), p=0.003) with a further increase on day one. [BNP] did not increase immediately after the marathon but increased on day one (median [BNP] before: 15 pg ml(-1), day one: 27.35 pg ml(-1), p=0.006)."}, {"qas": [{"id": "531d2aa5267d7dd053000003_004", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "Pro-BNP was significantly increased immediately post-race (27+/-21 vs 7+/-2 pmol/L pre-race, P < or = 0.007), which 12-24 h later, decreased to 19+/-14 pmol/L (P = 0.07 vs pre-race)."}, {"qas": [{"id": "531d2aa5267d7dd053000003_005", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "The relatively high NT-proBNP levels after active recovery when psychophysical stress is higher, because of cycling and cold water immersion, suggest that not only endurance exercise, but also strenuous, stressful short exercise can induce an increase in NT-proBNP concentrations."}, {"qas": [{"id": "531d2aa5267d7dd053000003_006", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "Running a marathon significantly increases NT-pro-BNP levels in healthy adults. This increase could be partially attributed to cardiac stress."}, {"qas": [{"id": "531d2aa5267d7dd053000003_007", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. The different nature of exercise-induced increases in BNP and cardiac troponins has to be elucidated in the future."}, {"qas": [{"id": "531d2aa5267d7dd053000003_008", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "In healthy cyclists, transient increases in NT-pro-BNP and cTnT are more likely to reflect cardiac fatigue than injury."}, {"qas": [{"id": "531d2aa5267d7dd053000003_009", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "The rise in BNP in older athletes may reflect a reversible, mainly diastolic left ventricular dysfunction. "}, {"qas": [{"id": "531d2aa5267d7dd053000003_010", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "Plasma BNP concentrations were higher in both the judo and marathon groups than in controls, and positively correlated with LV mass as well as with deceleration time."}, {"qas": [{"id": "531d2aa5267d7dd053000003_011", "question": "Does BNP increase after intensive exercise in athletes?", "is_impossible": false, "answers": "yes"}], "context": "Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_001", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Fibromyalgia Symptom Reduction by Online Behavioral Self-monitoring, "}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_002", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "This study aimed to evaluate effects of a web-based, self-monitoring and symptom management system (SMARTLog) that analyzes personal self-monitoring data and delivers data-based feedback over time."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_003", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Moderate use (3 times weekly x 3 months) increased likelihood of clinically significant improvements in pain, memory, gastrointestinal problems, depression, fatigue, and concentration; heavy use (4.5 times weekly x five months) produced the above plus improvement in stiffness and sleep difficulties."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_004", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Results suggest that the tailored online chronic pain management program showed promising effects on pain at 1 and 6 months posttreatment and quality of life at 6 months posttreatment in this naturalistic study."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_005", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_006", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Patient involvement can be fostered by web-based applications combining health information with decision support or behaviour change support. These so-called Interactive Health Communication Applications (IHCAs) can reach great numbers of patients at low financial cost and provide information and support at the time, place and learning speed patients prefer."}, {"qas": [{"id": "54fefff26ad7dcbc1200000b_007", "question": "Are there web based self management strategies for chronic pain ?", "is_impossible": false, "answers": "yes"}], "context": "Web-based interventions may also be effective in enhancing self-management for individuals with chronic pain, but little is known about long-term effects. Research on Web-based interventions to support self-management following participation in pain management programs is limited. OBJECTIVE: The aim is to examine the long-term effects of a 4-week smartphone-intervention "}, {"qas": [{"id": "571f34ac0fd6f91b68000005_001", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_002", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "NSD1 and EZH2 are SET domain-containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling: NSD1 preferentially methylates lysine residue 36 of histone 3 (H3K36) and is primarily associated with active transcription, while EZH2 shows specificity for lysine residue 27 (H3K27) and is associated with transcriptional repression"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_003", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_004", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_005", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Overgrowth syndromes such as Beckwith-Wiedemann syndrome, Sotos syndrome, and Weaver syndrome have an increased risk of neoplasia."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_006", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Thus, it is not surprising that prenatal overgrowth occurs in several syndromes, including the Sotos and Weaver syndromes."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_007", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_008", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "We conclude therefore that NSD1 mutations account for most cases of Sotos syndrome and a significant number of Weaver syndrome cases in our series."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_009", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "We conclude that intragenic mutations of NSD1 are the major cause of Sotos syndrome and account for some Weaver syndrome cases but rarely occur in other childhood overgrowth phenotypes."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_010", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Overgrowth syndromes such as Beckwith-Wiedemann syndrome, Sotos syndrome, and Weaver syndrome have an increased risk of neoplasia"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_011", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_012", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "We conclude that intragenic mutations of NSD1 are the major cause of Sotos syndrome and account for some Weaver syndrome cases but rarely occur in other childhood overgrowth phenotypes"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_013", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. "}, {"qas": [{"id": "571f34ac0fd6f91b68000005_014", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_015", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": " Overgrowth syndromes such as Beckwith-Wiedemann syndrome, Sotos syndrome, and Weaver syndrome have an increased risk of neoplasia. Two previous cases of neuroblastoma have been reported in children with Weaver syndrome."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_016", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Weaver syndrome is closely related to Sotos syndrome,"}, {"qas": [{"id": "571f34ac0fd6f91b68000005_017", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Overgrowth syndromes such as Beckwith-Wiedemann syndrome, Sotos syndrome, and Weaver syndrome have an increased risk of neoplasia."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_018", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident."}, {"qas": [{"id": "571f34ac0fd6f91b68000005_019", "question": "Is Weaver syndrome similar to Sotos?", "is_impossible": false, "answers": "yes"}], "context": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1."}, {"qas": [{"id": "553a8d78f321868558000003_001", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Starting from a genome-wide expression profiling, we demonstrate for the first time a functional link between oxygen deprivation and the modulation of long noncoding transcripts from ultraconserved regions, termed transcribed-ultraconserved regions (T-UCRs)"}, {"qas": [{"id": "553a8d78f321868558000003_002", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Our data gives a first glimpse of a novel functional hypoxic network comprising protein-coding transcripts and noncoding RNAs (ncRNAs) from the T-UCRs category"}, {"qas": [{"id": "553a8d78f321868558000003_003", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Highly conserved elements discovered in vertebrates are present in non-syntenic loci of tunicates, act as enhancers and can be transcribed during development"}, {"qas": [{"id": "553a8d78f321868558000003_004", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores. We refer to the elements as 'Olfactores conserved non-coding elements'"}, {"qas": [{"id": "553a8d78f321868558000003_005", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "We used a custom microarray to assess the levels of UCE transcription during mouse development and integrated these data with published microarray and next-generation sequencing datasets as well as with newly produced PCR validation experiments. We show that a large fraction of non-exonic UCEs is transcribed across all developmental stages examined from only one DNA strand. Although the nature of these transcripts remains a mistery, our meta-analysis of RNA-Seq datasets indicates that they are unlikely to be short RNAs and that some of them might encode nuclear transcripts"}, {"qas": [{"id": "553a8d78f321868558000003_006", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Our data shows that the concurrent presence of enhancer and transcript function in non-exonic UCE elements is more widespread than previously shown. Moreover through our own experiments as well as the use of next-generation sequencing datasets, we were able to show that the RNAs encoded by non-exonic UCEs are likely to be long RNAs transcribed from only one DNA strand"}, {"qas": [{"id": "553a8d78f321868558000003_007", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Short ultraconserved promoter regions delineate a class of preferentially expressed alternatively spliced transcripts"}, {"qas": [{"id": "553a8d78f321868558000003_008", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "The importance of other classes of non-coding RNAs, such as long intergenic ncRNAs (lincRNAs) and transcribed ultraconserved regions (T-UCRs) as altered elements in neoplasia, is also gaining recognition."}, {"qas": [{"id": "553a8d78f321868558000003_009", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Other ncRNAs, such as PIWI-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), transcribed ultraconserved regions (T-UCRs) and large intergenic non-coding RNAs (lincRNAs) are emerging as key elements of cellular homeostasis."}, {"qas": [{"id": "553a8d78f321868558000003_010", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores."}, {"qas": [{"id": "553a8d78f321868558000003_011", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Transcribed ultraconserved regions (T-UCRs) are a subset of 481 sequences longer than 200 bp, which are absolutely conserved between orthologous regions of human, rat and mouse genomes, and are actively transcribed."}, {"qas": [{"id": "553a8d78f321868558000003_012", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Highly conserved elements discovered in vertebrates are present in non-syntenic loci of tunicates, act as enhancers and can be transcribed during development."}, {"qas": [{"id": "553a8d78f321868558000003_013", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator."}, {"qas": [{"id": "553a8d78f321868558000003_014", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "In this report, we show that the Dlx-5/6 ultraconserved region is transcribed to generate an alternatively spliced form of Evf-1, the ncRNA Evf-2."}, {"qas": [{"id": "553a8d78f321868558000003_015", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "These studies identify a critical role for TUC338 in regulation of transformed cell growth and of transcribed ultraconserved ncRNA as a unique class of genes involved in the pathobiology of HCC."}, {"qas": [{"id": "553a8d78f321868558000003_016", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Transcribed ultraconserved region (T-UCR) transcripts are a novel class of lncRNAs transcribed from ultraconserved regions (UCRs)"}, {"qas": [{"id": "553a8d78f321868558000003_017", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores"}, {"qas": [{"id": "553a8d78f321868558000003_018", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Transcribed ultraconserved regions (T-UCRs) are a subset of 481 sequences longer than 200 bp, which are absolutely conserved between orthologous regions of human, rat and mouse genomes, and are actively transcribed"}, {"qas": [{"id": "553a8d78f321868558000003_019", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Other ncRNAs, such as PIWI-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), transcribed ultraconserved regions (T-UCRs) and large intergenic non-coding RNAs (lincRNAs) are emerging as key elements of cellular homeostasis"}, {"qas": [{"id": "553a8d78f321868558000003_020", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Transcribed ultraconserved region in human cancers."}, {"qas": [{"id": "553a8d78f321868558000003_021", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "We show that a large fraction of non-exonic UCEs is transcribed across all developmental stages examined from only one DNA strand"}, {"qas": [{"id": "553a8d78f321868558000003_022", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Although uc.338 is partially located within the poly(rC) binding protein 2 (PCBP2) gene, the transcribed ncRNA encoding uc.338 is expressed independently of PCBP2 and was cloned as a 590-bp RNA gene, termed TUC338"}, {"qas": [{"id": "553a8d78f321868558000003_023", "question": "Are ultraconserved elements often transcribed?", "is_impossible": false, "answers": "yes"}], "context": "Moreover through our own experiments as well as the use of next-generation sequencing datasets, we were able to show that the RNAs encoded by non-exonic UCEs are likely to be long RNAs transcribed from only one DNA strand."}, {"qas": [{"id": "552fa6f5bc4f83e828000002_001", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "The term \"small round-cell tumor\" describes a group of highly aggressive malignant tumors composed of relatively small and monotonous undifferentiated cells with high nuclear to cytoplasmic ratios. This group includes Ewing's sarcoma (ES), peripheral neuroepithelioma (aka, primitive neuroectodermal tumor or extraskeletal ES), peripheral neuroblastoma (\"classic-type\"), rhabdomyosarcoma, desmoplastic small round-cell tumor, lymphoma, leukemia, small-cell osteosarcoma, small-cell carcinoma (either undifferentiated or neuroendocrine), olfactory neuroblastoma, cutaneous neuroendocrine carcinoma (aka, Merkel-cell carcinoma), small-cell melanoma, and mesenchymal chondrosarcoma. Their clinical presentations often overlap, thus making a definitive diagnosis problematic in some cases"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_002", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "AIMS: To retrospectively study the DNA content in a series of childhood Ewing Family Tumors (EFT), and to investigate its prognostic value. METHODS: The study was performed on a series of 27 EFTs (osseous Ewing's sarcoma, 18 cases; extraosseous Ewing's sarcoma, 2; peripheral neuroepithelioma, 4; Askin Rosai tumors, 3"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_003", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's sarcoma)"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_004", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "Large group of small-round-cell tumours of soft tissues and bone represents a complex diagnostic problem for the pathologists. Neuronal nature of many tumours from this group is proven by means of new methods--immunophenotypic analysis, tissue culture, cytogenetics. Peripheral neuroepithelioma, Ewing tumour, primitive neuroectodermal tumour (PNET), Askin tumour belong to these neoplasms"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_005", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_006", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "Ewing's sarcoma of bone (ESB) and peripheral neuroepithelioma (PN) are frequently considered to be different tumors. Some researchers have suggested that PN is morphologically a neuroectodermal Ewing's sarcoma. We sought to determine the extent of neuroectodermal features in conventional ESB on direct patient material (25 cases) and to compare these tumors with a similar group of readily diagnosed PNs (10 cases)"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_007", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "Neuroectodermal antigens (neuron-specific enolase, Leu-7 [HNK-1], neurofilament 200 kd, and S100) were found in nine of 10 cases of PN and in 17 of 25 cases of ESB"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_008", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "These data support the concept that ESB and PN are both peripheral primitive neuroectodermal neoplasms, differing only in extent of neuroectodermal phenotype and morphological differentiation"}, {"qas": [{"id": "552fa6f5bc4f83e828000002_009", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "is_impossible": false, "answers": "yes"}], "context": "Besides these antigenic features, Ewing sarcoma cells are characterized by a specific t(11;22)(q24;q12) translocation also observed in neuroepithelioma, a neuroectodermal tumor, suggesting a possible evolutionary related origin."}]}]}